Videos

This week, we look at a cross-industry shift toward integrated automation, domestic resilience, and a critical focus on the human talent pipeline.

PharmTech Weekly Roundup - February 6, 2026

Marcio Temtem, vice president, Strategic Business Management, Hovione, addresses molecule complexity, speed, and regionalization via integrated manufacturing.

Hovione’s Strategy for Complexity, Speed, and Regional Supply Chains

Oncologist Dr. Maria de Miguel, MD, PhD, MBA, Director, Clinical Research for START Rioja, spoke with PharmTech about the importance of STEM education in early phase drug development.

Women in STEM: Early Phase Drug Development

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Walid Kamoun, PhD, and Alex Philippidis discuss AI’s Power to Lower Costs while Elucidating Tumor Progression, NVIDIA and Eli Lily’s Deal, and Revolution Medicine’s lack of a Deal.

Behind the Headlines Episode 32: AI’s Power, NVIDIA & Lilly, Revolution Medicine

Anthony Lakavage, executive vice president and head of Global External Affairs at USP, talks about how sustainability efforts are more than just protecting the environment and how pharmaceopeias are participating in the endeavor.

The Role of Standards in Sustainability

This week's coverage discusses the M&A report, $50B+ investments, automated cell therapy, vaccine approvals, and risks from the US leaving the WHO.

PharmTech Weekly News Roundup – Week of January 26, 2026

In a 2026 industry outlook interview, Raj Puri explains balancing speed with the financial and regulatory risks of accelerated drug launches via alignment.

Navigating the Complex Risks of Accelerated Pharmaceutical Launches

In a 2026 industry outlook interview, Raj Puri discusses how the tariffs hinder US pharma investment but drive demand for geographically segregated supply chains.

Balancing Unpredictable Tariffs with Geographically Segregated Supply Chains

With a potential US government shutdown looming, Megha Sinha, Kamet Consulting, says to treat FDA disruptions as predictable risks by protecting milestones and early readiness.

US Government Shutdown: Treating Regulatory Lapses as Predictable Operational Risks

With a potential US government shutdown looming, Megha Sinha, Kamet Consulting, discusses the impacts on pharma manufacturing and development.

PharmTech Videos